Market Report Source

Overview

This report provides comprehensive coverage of the major GIT markets, incorporating a detailed epidemiological analysis of the major indications and key factors impacting their prevalence; using IMS data, it provides analysis of current leading brands of treatment within each GIT indication provides an invaluable insight into the dynamics of the market, while profiling the pharmaceutical companies and relevant market trends that influence the sales of GIT treatments. This report further provides forecasts of major products over the 2005-10 period and the underlying trends affecting the future of the GIT market. By providing coverage of over 90% of the total market for GIT products and highlighting key players, this report allows the reader to gain a thorough understanding of the issues that are driving the transformation of the GIT market, and understand the likely direction that this market will take over the next 5 years.

Table of Contents

Table of Contents

The Gastrointestinal Market Outlook to

Executive Summary

Patient potential

Global market analysis

Leading players in the global GIT market

Analysis of potential future GIT blockbusters

Chapter 1 Patient potential

Summary

Introduction

Gastroesophageal reflux disorder

Background

Prevalence

Forecast prevalence

Peptic ulcer disease

Background

Prevalence

Forecast prevalence

Irritable bowel syndrome

Background

Prevalence

Forecast prevalence

Ulcerative colitis

Background

Prevalence

Forecast prevalence

Crohn’s disease

Background

Prevalence

Forecast prevalence

iv

Chapter 2 Global market analysis

Summary

Introduction

The global GIT market

Leading products

Gastroesophageal reflux disorder and peptic ulcer disease

Introduction

Analysis of the leading GERD/PUD treatments

Market analysis by drug class

Histamine-2 receptor antagonists

Proton pump inhibitors

GERD/PUD sales forecasts

Irritable bowel syndrome

Introduction

Analysis of the leading IBS treatments

Market analysis by drug class

GI sensorimotor modulators

Anti-spasmodics/anti-cholinergics

IBS sales forecasts

Crohn’s disease and ulcerative colitis

Introduction

Analysis of the leading IBD treatments

Market analysis by drug class

Immunosuppressive agents

Intestinal anti-inflammatory agents

Crohn’s disease and ulcerative colitis sales forecasts

Chapter 3 Leading players in the global GIT market

Summary

Introduction

Global market shares

AstraZeneca

Marketed products

R&D compounds

GIT portfolio forecasts to 2010

Wyeth

Marketed products

R&D compounds

GIT portfolio forecasts to 2010

Johnson & Johnson

v

Marketed products

R&D compounds

GIT portfolio forecasts to 2010

Amgen

Marketed products

R&D compounds

GIT portfolio forecasts to 2010

Abbott

Marketed products

R&D compounds

GIT portfolio forecasts to 2010

Takeda

Marketed products

R&D compounds

GIT portfolio forecasts to 2010

Eisai

Marketed products

R&D compounds

GIT portfolio forecasts to 2010

Novartis

Marketed products

R&D compounds

GIT portfolio forecasts to 2010

Chapter 4 Analysis of potential future GIT blockbusters

Summary

Introduction

Drug profiles

Calmactin (cilansetron)

Prograf (tacrolimus)

Ramosetron

Cimzia (certolizumab)

Humira (adalimumab)

Tysabri (natalizumab)

Alicaforsen (ISIS 2302)

PTI-901

Renzapride

OPC-6535

TAK-390MR

Lubiprostone (SPI-0211)

ABT-874

vi

Chapter 5 Appendix

IMS data

Countries covered

ATC categories

Glossary

Index

References

List of Figures

Figure 2.1: Competitive dynamics in the global GIT market, 2004

Figure 2.2: Competitive dynamics among leading brands in the global GIT market, 2004

Figure 2.3: Competitive dynamics in the GERD/PUD market, 2004

Figure 2.4: Competitive dynamics of the leading brands in the

Figure 2.5: Competitive dynamics in the IBS market, 2004

Figure 2.6: Competitive dynamics of leading brands in the IBS market, 2004

Figure 2.7: Competitive dynamics in the IBD market, 2004

Figure 2.8: Competitive dynamics in of leading brands in the IBD market, 2004

Figure 3.9: Key players in the global GIT market, 2000 and 2004

Figure 4.10: Leading GIT drugs in development, 2005

List of Tables

Table 1.1: Estimated prevalence of GERD in the seven major pharmaceutical markets, 2004

Table 1.2: Estimated prevalence of GERD in the seven major pharmaceutical markets, 2005–

Table 1.3: Estimated prevalence of PUD in the seven major pharmaceutical markets, 2004

Table 1.4: Estimated prevalence of PUD in the seven major pharmaceutical markets, 2005–10

Table 1.5: Estimated prevalence of IBS in the seven major pharmaceutical markets, 2004

Table 1.6: Estimated prevalence of IBS in the seven major pharmaceutical markets, 2005–10

Table 1.7: Estimated prevalence of UC in the seven major pharmaceutical markets, 2004

Table 1.8: Estimated prevalence of UC in the seven major pharmaceutical markets, 2005–10

Table 1.9: Estimated prevalence of CD in the seven major pharmaceutical markets, 2004

Table 1.10: Estimated prevalence of CD in the global market, 2005–10

Table 2.11: Breakdown of the global GIT market by drug class, 2000-04

Table 2.12: Leading products in the global GIT market, 2003–04

Table 2.13: Breakdown of the global GERD and PUD market by drug class, 2003-04

Table 2.14: Breakdown of the global GERD/PUD market by leading brands, 2003-04

Table 2.15: Sales forecasts for GERD/PUD therapies in the global market, 2004–10

Table 2.16: Breakdown of the global IBS market by drug class, 2003-04

Table 2.17: Breakdown of the global IBS market by leading brands, 2003-04

vii

Table 2.18: Sales forecasts for IBS therapies in the global market, 2004–10

Table 2.19: Breakdown of the global IBD market by drug class, 2003-04

Table 2.20: Breakdown of the global IBD market by leading brands, 2003-04

Table 2.21: Sales forecasts for IBD therapies in the global market, 2004–10

Table 3.22: Key players in the global GIT market, 2004

Table 3.23: AstraZeneca’s marketed GIT portfolio, 2004

Table 3.24: AstraZeneca’s GIT R&D pipeline, 2005

Table 3.25: Forecast sales for AstraZeneca’s GIT portfolio, 2004–10

Table 3.26: Wyeth’s’ marketed GIT portfolio, 2004

Table 3.27: Forecast sales for Wyeth’s GIT portfolio, 2004–10

Table 3.28: J&J’s marketed GIT portfolio, 2004

Table 3.29: J&J’s GIT R&D pipeline, 2005

Table 3.30: Forecast sales for J&J’s GIT portfolio, 2004–10

Table 3.31: Amgen’s marketed GIT portfolio, 2004

Table 3.32: Forecast sales for Amgen’s GIT portfolio, 2004–10

Table 3.33: Abbott’s marketed GIT portfolio, 2004

Table 3.34: Abbott’s GIT R&D pipeline, 2005

Table 3.35: Forecast sales for Abbott’s GIT portfolio, 2004–10

Table 3.36: Takeda’s marketed GIT portfolio, 2004

Table 3.37: Takeda’s GIT R&D pipeline, 2005

Table 3.38: Forecast sales for Takeda’s GIT portfolio, 2004–10

Table 3.39: Eisai’s marketed GIT portfolio, 2004

Table 3.40: Eisai’s GIT R&D pipeline, 2005

Table 3.41: Forecast sales for Eisai’s GIT portfolio, 2004–10

Table 3.42: Novartis’ marketed GIT portfolio, 2004

Table 3.43: Novartis’ GIT R&D pipeline, 2005

Table 3.44: Forecast sales for Novartis’ GIT portfolio, 2004–10 126